Although anti-TSLP biologic treatment reduces exacerbations in severe asthmatics and it is assumed to suppress viral-induced ILC2-mediated eosinophilic inflammation as proven in a murine model [6], the definite effect of such a treatment on viral-induced innate responses and ILC2 activation in patients with asthma needs further assessment [72]. This evidence concerns the gene TSLP and asthma.